ClinicalTrials.gg

Program

obecabtagene autoleucel

Also written as “AUTO1”, “Obecabtagene autoleucel (obe-cel)” and “Obecabtagene autoleucel”.

Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Lupus Erythematosus, Systemic, led by Autolus.

Furthest: phase 2, since May 12, 20205 company-led studies, 5 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Autolus55 open or runningphase 2since May 12, 2020May 12, 2020Sep 2027phase 1 · NCT06333483

Also a collaborator on its studies: PPD Development, LP.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2020First study: phase 2 study in RecurrenceFirst studyNCT04404660 · 153 enrolled · United States, Spain, United Kingdom
  2. Dec 8, 2023Phase 1 study in RecurrenceNCT06173518 · 30 planned · United States, Spain, United Kingdom
  3. Mar 6, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06333483 · 16 enrolled · Spain, United Kingdom
  4. May 13, 2025Phase 2 study in Lupus NephritisNCT07053800 · 35 planned · United States, Brazil, Greece and more
  5. Aug 18, 2025Phase 1 study in Multiple Sclerosis, Chronic ProgressiveNCT07139743 · 24 planned · United States, Spain, United Kingdom

Ahead

  1. Sep 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06333483
  2. Nov 2027Primary completion: phase 1 study in RecurrenceNCT06173518
  3. Aug 2028Primary completion: phase 2 study in Lupus NephritisNCT07053800
  4. Jun 30, 2029Primary completion: phase 2 study in RecurrenceNCT04404660

TargetBeta

CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with immunostimulating and antineoplastic activities”NCIt, by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07139743Multiple Sclerosis, Chronic Progressive · United States, Spain, United Kingdom1RecruitingAug 15, 202924
NCT07053800Lupus Nephritis · United States, Brazil, Greece and more2RecruitingAug 202835
NCT06333483Lupus Erythematosus, Systemic · Spain, United Kingdom1Active, not recruitingSep 202716
NCT06173518Recurrence · United States, Spain, United Kingdom1RecruitingNov 202730
NCT04404660Recurrence · United States, Spain, United Kingdom2Active, not recruitingJun 30, 2029153

How it is read

Names in the registry

  • “AUTO1”, 2 entries
  • “Obecabtagene autoleucel (obe-cel)”, 2 entries
  • “Obecabtagene autoleucel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.